Table 1 Detail of patient groups

From: Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis

 

Training SELDI

Validation-1 SELDI

Validation-2 ELISA

 

n

n

n

Pancreatic ductal adenocarcinoma

38

40

33

 Male

20

23

15

 Female

18

17

18

 Stage I

7

—

1

 Stage IIa

5

4

7

 Stage IIb

8

36

14

 Stage IV

18

—

11

Disease control

54

21

28

 Male

28

18

16

 Female

26

3

12

 Cholelithiasis

17

2

 

 Choledocholithiasis

  

6

 Intraductal papillary mucinous neoplasm

6

—

1

 Carotid artery stenosis

—

6

 

 Mucinous cystadenoma

5

—

2

 Neuroendocrine (islet cell) tumour

5

—

7 (4)

 Gallstone pancreatitis

4

—

2

 Chronic pancreatitis

4

1

2

 Benign stricture

  

2

 Hernia

3

2

 

 Acute cholecystitis

—

3

 

 Othera

10

7

3

Healthy volunteer

68

19

18

 Male

28

12

9

 Female

40

7

9

  1. Abbreviation: SELDI=surface-enhanced laser desorption and ionisation.
  2. The number in brackets indicates malignant islet cell tumours.
  3. aOther includes: Training Set – villous adenoma (n=2), serous cystadenoma (n=2), pancreatic pseudocyst (n=2), solid pseudopapillary tumour (n=1), Caroli's disease (n=1), gastro-oesophageal reflux (n=1) and ruptured appendix (n=1); Validation-1 Set – leg ischaemia (n=2), rectal bleeding (n=2), diaphragmatic hernia (n=1), phlebitis (n=1) and haematological disorder (n=1); and Validation-2 Set – solitary fibrous tumour, granulomata, intrapancreatic pseudocyst.
Back to article page